Home DSM-Firmenich China President Zhou Tao: China Bolsters Multinationals' Confidence in Long-Term Growth | Voices from the 2026 Two Sessions

DSM-Firmenich China President Zhou Tao: China Bolsters Multinationals' Confidence in Long-Term Growth | Voices from the 2026 Two Sessions

Mar 13, 2026 18:23 CST Updated 18:23

2026 China Two Sessions Observation“Special Report

•  2026 China’s Two Sessions: Targeting the “Last Mile” in the Implementation of Innovative Drugs | 2026 Two Sessions Policy Analysis

•  Li Yan, NPC Deputy and President of Qilu Pharmaceutical Group: Enhancing the Quality of Elderly Health Services and Accelerating the “Medical-Pharmaceutical-Rehabilitation” Closed Loop | 2026 Two Sessions Policy Insights



“Standing at this pivotal juncture in 2026, the inaugural year of the 15th Five-Year Plan, which serves as a link between the past and the future, we deeply feel the surging vitality of the Chinese market. The Chinese government continues to optimize the consumer market and promote the deep integration of technological innovation with industrial innovation, providing for including”DSM-Firmenich“...has injected strong confidence into the long-term development of multinational enterprises in China,” Zhou Tao, President of DSM-Firmenich China, told VCBeat recently.

图片 

微信图片_2026-03-13_174243_098.jpg

Zhou Tao, President of DSM-Firmenich China


According to official company information, as an innovator in the fields of nutrition, health, and beauty, dsm-firmenich reimagines, manufactures, and combines essential nutrients, flavors, and fragrances. From fine fragrances to agriculture, and from food and beverage solutions to micronutrients, its business units meet consumer needs in a sustainable manner.


In China, dsm-firmenich’s trade history dates back to 1963. After more than six decades of dedicated development, the company now employs approximately 5,000 people and operates over 40 entities and branches in the country, including four R&D centers and more than ten production bases.


In Zhou Tao’s view, as China’s consumption structure continues to upgrade, the consumer market is continually unleashing its potential in the fields of nutrition, health, and beauty, with nutritional and health-focused food products,Silver Economy, the fragrance economy, and self-rewarding consumption are emerging sectors demonstrating strong growth potential. This not only aligns closely with dsm-firmenich’s core business strategy but also opens up broader development opportunities for the company’s deepened expansion in the Chinese market.


According to reports, dsm-firmenich has always upheld its corporate mission of “Brighter Living,” leveraging its strengths in science and innovation, along with localized R&D and strategic partnerships, to actively contribute to the continuous improvement of people’s livelihoods and the quality enhancement and expansion of consumer services.


Meanwhile, as a responsible corporate citizen, dsm-firmenich has always adhered to the concept of business for good and actively practiced its corporate social responsibility.


Zhou Tao further informed VCBeat that, since 2023, the company has launched the “DSM-Firmenich Beauty for Good Development Initiative” for three consecutive years. The initiative aims to leverage its professional expertise in nutrition, health, and beauty to empower Chinese women and their families, enhance overall well-being, and contribute to the “Healthy China 2030” initiative.


“During the project period, the company partnered with the China Foundation for Rural Development to deliver online and offline empowerment programs focused on nutrition, health, and beauty knowledge. To date, the project has benefited nearly 1,000 ‘Tongban’ mothers, impacting over 200,000 children in rural China and their family members, with cumulative online content views exceeding 9 million.”


“In the future, we will join hands with partners across the industry chain to continuously deepen collaborative efforts in the fields of nutrition, health, and beauty. With a more focused approach, we aim to empower industrial upgrading and contribute to China’s high-quality development and the well-being of its people,” said Zhou Tao.图片


- [Invitation] -

2026 Future Healthcare & Pharma Top 100 Conference


Forum on Tackling the “Last Mile” Challenges in Realizing the Value of Innovative Drugs

From Clinic to Market, from Valuation to Value


A Wave of Innovative Drugs Hits the Market, but “Approval” Does Not Equal “Accessibility.”

Health Insurance Reimbursement Inclusion, Payment Bottlenecks, Channel Barriers… How Can Clinical Value Be Translated into Market Value?

Policy Reshaping, Capital on the Sidelines: How Can Enterprises Navigate the Cycle Amid Uncertainty?


Join the “Final Mile Breakthrough Forum on Realizing the Value of Innovative Drugs,” where we discuss not only trends but also solutions.

● Focus on Three Core Value Chains:Commercialization Strategy, Innovative Payment, Capital Empowerment;

● Dialogue with Leading Experts: Chief Business Officer, Health Insurance Expert, Commercial Insurance Pioneer, Capital Industry Leader;

● Practical Perspectives on Capital Empowerment: An in-depth exploration of how capital empowers enterprises during the commercialization stage;

● Review of Successful Cases: A Comprehensive Breakdown of Market Access Strategies, Payment Design, Channel Layout, and Capital Operations;

● Roundtable Debate: How can a value community be built through multi-party collaboration? How can the integration of industry and finance be implemented?


What You Will Gain:

● Identifying Breakthrough Paths Amidst the Interplay of Policy and Market Forces

● Connecting decision-makers, payers, investors, and channel partners

● Transforming brand exposure from mere dissemination into tangible commercial connections


● Time: May 19, 2026, 14:00–17:30

● Location: Shanghai Minhang District Baijin Hanjue Hotel

● Organizer: VCBeat


Add the WeChat ID below to register and secure your limited attendee/guest spot.

Together, let’s bridge the “last mile” for innovative drugs!


img_v3_02u3_437a2ef3-2938-4a44-8c0e-c7555f19a42g.png